Nov 12, 2026 | Press Releases
Highlighting Phio’s Differentiated, Paradigm-Shifting Treatment Approach for Skin CancerLive Presentation and Q&A: Wednesday, November 18, 2026 2 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – November 12, 2026) – Phio...
Nov 9, 2026 | Press Releases
INTASYL siRNA – Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of Prussia, Pennsylvania–(Newsfile Corp. – November 9, 2026) – Phio Pharmaceuticals Corp....
Nov 6, 2026 | Press Releases
INTASYL siRNA – Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – November 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Nov 5, 2026 | Press Releases
PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDAKing of Prussia, Pennsylvania–(Newsfile Corp. –...
Oct 19, 2026 | Press Releases
Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – October 19, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...
Oct 13, 2026 | Press Releases
Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania–(Newsfile Corp. – October 13, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...